Pharmacogenetic Considerations in Beta-Blocker Therapy
SMART-MD Journal of Precision Medicine · 2024
DOI: 10.69734/hpaezm84 ↗Kurz gefasst
Fachartikel in der Zeitschrift SMART-MD Journal of Precision Medicine, 2024. Verfasst von Bennie Yang und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pharmacogenetic testing offers a promising approach to personalizing beta-blocker therapy which is used for a variety of diseases, such as heart failure, myocardial infarction and migraine prophylaxis. The genetic variability in the metabolism and response to beta-blockers such as metoprolol can significantly influence treatment outcomes. Understanding these genetic differences can help optimize therapy and minimize adverse effects. A brief summary of the current guideline and recommendations: Approximately 0.3-6.5% (depending on their ancestry) of patients are CYP2D6 poor metabolizers. CYP2D6 Poor Metabolizers have significantly decreased metabolism of metoprolol, leading to increased drug concentration and a higher risk of adverse effects. The highest dose of metoprolol that patients can tolerate may be lower in CYP2D6 poor metabolizers compared to those that are non-poor CYP2D6 metabolizers. Current evidence is insufficient to support routine clinical testing or therapeutic adjustments for other genes affecting beta-blocker pharmacodynamics, such as ADRB1, ADRB2, ADRA2C, and GRK5. Future research should consider the combined effects of multiple genetic variants (e.g., polygenic risk scores) rather than focusing solely on single-gene associations.
Zitieren
APA
Yang, B., & Luzum, J. (2024). Pharmacogenetic Considerations in Beta-Blocker Therapy. SMART-MD Journal of Precision Medicine. https://doi.org/10.69734/hpaezm84
Vancouver
Yang B, Luzum J. Pharmacogenetic Considerations in Beta-Blocker Therapy. SMART-MD Journal of Precision Medicine. 2024. doi:10.69734/hpaezm84
BibTeX
@article{Yang2024,
author = {Yang, Bennie and Luzum, Jasmine},
title = {Pharmacogenetic Considerations in Beta-Blocker Therapy},
journal = {SMART-MD Journal of Precision Medicine},
year = {2024},
doi = {10.69734/hpaezm84}
}
EUVIMED